5 Results for "

Synergism

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "Synergism" in MCE Product Catalog:

Cat. No.: HY-157068
CAS No.: 1115910-36-5
Purity:  99.94%
Research Areas:  

Cancer

icFSP1 is a potent ferroptosis suppressor protein-1 (FSP1) inhibitor. icFSP1 triggers subcellular relocalization of FSP1 from the membrane and FSP1 condensation, in synergism with GPX4 inhibition. icFSP1 induces ferroptosis. icFSP1 shows antitumor activity against melanoma. .
loading...
    loading...
Cat. No.: HY-106605
CAS No.: 61325-80-2
Synonyms: LY 120363
Research Areas:  

Neurological Disease

Flumezapine (LY 120363) is a potent and balanced antagonist of the dopamine D2 receptor and the 5-hydroxytryptamine receptor (5-HT receptor). Flumezapine does not alter the increase in serum cortisol caused by κ-opioid receptor agonists. Flumezapine inhibits the conditioned avoidance response in rats and has a low risk of extrapyramidal side effects. Flumezapine can be used in antipsychotic research .
loading...
    loading...
Cat. No.: HY-108238
CAS No.: 142404-10-2
Target:  

PARP

Research Areas:  

Cancer

BSI-401 is an orally active PARP-1 inhibitor. BSI-401 alone and in synergism with Oxaliplatin (HY-17371) inhibits pancreatic cancer .
loading...
    loading...
Cat. No.: HY-106072
CAS No.: 67699-40-5
Synonyms: LY 104208
Target:  

Microtubule/Tubulin

Research Areas:  

Cancer

Vinzolidine is a semisynthetic derivative of the catharanthus alkaloid. Vinzolidine exerts its cytotoxic effect on tumor cells by interfering with microtubulin polymerization, thereby inhibiting cell division. Vinzolidine can be utilized in research to investigate synergistic effects when combined with other chemotherapeutic agents or biologic therapies, as well as to study cancer cells' tolerance or resistance to these treatments, and to explore approaches to overcome such obstacles .
loading...
    loading...
Cat. No.: HY-165540
CAS No.: 1001468-07-0
Research Areas:  

Infection

BDM31343 is an Ethionamide (HY-B0276) synergist. BDM31343 inhibits the transcriptional repressor EthR in Mycobacterium tuberculosis, thereby relieving the inhibition of the EthA activator by Ethionamide, and enhancing the efficacy of Ethionamide. BDM31343 effectively inhibits the binding of EthR to DNA, with its IC₅₀ being 3.3 μM. BDM31343 can be used in the research of anti-Mycobacterium tuberculosis .
loading...
    loading...